Erste Asset Management Gmb H Reata Pharmaceuticals Inc Transaction History

Erste Asset Management Gmb H

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 26, 2024	SELL	$0.0 - $172.36 $0 - $0	0 Closed	0 $0
Q1 2023 Nov 26, 2024	BUY	$30.85 - $93.17 $709,550 - $2.14 Million	23,000 New	23,000 $2.07 Billion
Q4 2022 Nov 26, 2024	BUY	$22.15 - $42.11 $0 - $0	0 New	0 $0
Q3 2022 Nov 26, 2024	BUY	$19.41 - $36.49 $0 - $0	0 New	0 $0
Q2 2022 Nov 26, 2024	BUY	$20.71 - $36.5 $0 - $0	0 New	0 $0
Q1 2022 Nov 22, 2024	SELL	$24.12 - $39.6 $426,924 - $700,920	-17,700 Closed	0 $0
Q4 2021 Nov 22, 2024	BUY	$25.61 - $110.96 $171,587 - $743,432	6,700 New	6,700 $172 Million
Q4 2020 Nov 22, 2024	SELL	$102.03 - $184.62 $499,947 - $904,638	-4,900 Reduced 21.68%	17,700 $2.3 Billion
Q3 2020 Nov 22, 2024	BUY	$93.53 - $163.34 $2.11 Million - $3.69 Million	22,600 New	22,600 $2.14 Billion
Q4 2019 Nov 22, 2024	BUY	$74.57 - $217.92 $1.69 Million - $4.92 Million	22,600 New	22,600 $4.78 Billion
Q2 2019 Nov 22, 2024	BUY	$77.72 - $94.35 $1.76 Million - $2.13 Million	22,600 New	22,600 $2.07 Billion

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.